Celgene defends REMS patents against Kyle Bass' IPR petitions
Client(s) Celgene Corporation
Jones Day is representing Celgene Corporation in defending four IPR petitions filed by Coalition for Affordable Drugs VI LLC - a company formed by hedge fund manager Kyle Bass - against U.S. Patent Nos. 6,045,501 and 6,315,720, which are listed in the Orange Book for Celgene's REVLIMID®, POMALYST®, and THALOMID® brand drugs, and which pertain to Celgene's Risk Evaluation and Mitigation Strategy (REMS)™ for those drugs.
Coalition for Affordable Drugs VI LLC et al. v. Celgene Corporation, IPR2015-01102 (PTAB)